Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: PRIZE - Project Grant - PA: Prize: Early Career Investigator in Cancer

University of Toronto

$25,000.00

Prize 202209PJT - Early Career Award in Cancer: A unified approach to determine how MUS81-EME1 recognizes and cleaves branched DNA structures to safeguard genome integrity

EF 2022-23

Résumé
Cancer is a leading cause of death worldwide. One hallmark of cancer cells is a high frequency of mutations and DNA rearrangements, collectively known as genome instability. Persistent DNA damage fuels genome instability and paradoxically, genomes are constantly exposed to a plethora of DNA-damaging agents. Cells use sophisticated pathways to repair DNA damage and preserve genome integrity. Determining how these pathways operate is a top priority for foundational and translational scientists. Most DNA repair pathways require nucleases to cut and remove damaged or abnormal DNA structures. However, without tight regulatory mechanisms, nucleases can catalyze catastrophic chromosome cleavage. There is burgeoning interest in leveraging this activity to sensitive cancer cells to anti-cancer drugs. Understanding how DNA nucleases recognize and cleave their DNA substrates will identify novel targets for therapeutic intervention. My research addresses these questions through the SMX tri-nuclease, which contains three nucleases, SLX1, MUS81-EME1 and XPF-ERCC1, bound to the SLX4 scaffold. Cells rely on SMX for accurate DNA repair and genome stability, although its untimely activation triggers chromosome pulverization. My research has defined mechanisms of SMX assembly and activation. Remarkably, MUS81-EME1 is responsible for most of the nuclease activities ascribed to SMX. We discovered a non-catalytic domain in MUS81 as the linchpin for targeted recognition of abnormal DNA structures (substrate specificity). We will use biochemical and cellular approaches to determine how this domain controls MUS81-EME1's substrate specificity and elucidate the biological consequences of relaxed substrate specificity in different cellular contexts. These studies will significantly advance our understanding of how MUS81-EME1 safeguards genome integrity. Likewise, our research will provide a solid framework for future research aimed at identifying compounds that target MUS81 in cancer cells.
Programme
PRIZE - Project Grant - PA: Prize: Early Career Investigator in Cancer
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
477687
Name
Wyatt Haley D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Prize 202209PJT - Early Career Award in Cancer: A unified approach to determine how MUS81-EME1 recognizes and cleaves branched DNA structures to safeguard genome integrity
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
PRIZE - Project Grant - PA: Prize: Early Career Investigator in Cancer
Keyworddelim
Biochemistry; Cancer; Cellular Senescence; Dna Repair; Genome Stability; Molecular Biology; Mus81-Eme1; Replication Stress; Slx4; Structure-Selective Endonuclease
Abstract
Cancer is a leading cause of death worldwide. One hallmark of cancer cells is a high frequency of mutations and DNA rearrangements, collectively known as genome instability. Persistent DNA damage fuels genome instability and paradoxically, genomes are constantly exposed to a plethora of DNA-damaging agents. Cells use sophisticated pathways to repair DNA damage and preserve genome integrity. Determining how these pathways operate is a top priority for foundational and translational scientists. Most DNA repair pathways require nucleases to cut and remove damaged or abnormal DNA structures. However, without tight regulatory mechanisms, nucleases can catalyze catastrophic chromosome cleavage. There is burgeoning interest in leveraging this activity to sensitive cancer cells to anti-cancer drugs. Understanding how DNA nucleases recognize and cleave their DNA substrates will identify novel targets for therapeutic intervention. My research addresses these questions through the SMX tri-nuclease, which contains three nucleases, SLX1, MUS81-EME1 and XPF-ERCC1, bound to the SLX4 scaffold. Cells rely on SMX for accurate DNA repair and genome stability, although its untimely activation triggers chromosome pulverization. My research has defined mechanisms of SMX assembly and activation. Remarkably, MUS81-EME1 is responsible for most of the nuclease activities ascribed to SMX. We discovered a non-catalytic domain in MUS81 as the linchpin for targeted recognition of abnormal DNA structures (substrate specificity). We will use biochemical and cellular approaches to determine how this domain controls MUS81-EME1's substrate specificity and elucidate the biological consequences of relaxed substrate specificity in different cellular contexts. These studies will significantly advance our understanding of how MUS81-EME1 safeguards genome integrity. Likewise, our research will provide a solid framework for future research aimed at identifying compounds that target MUS81 in cancer cells.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wyatt, Haley D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $25,000~ $0~